The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 15, 2022

Filed:

Aug. 10, 2020
Applicant:

Quest Diagnostics Investments Llc, Secaucus, NJ (US);

Inventor:

Maher Albitar, Coto De Caza, CA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/6883 (2018.01); G01N 33/574 (2006.01); A61K 31/497 (2006.01); A61K 31/506 (2006.01); C07K 14/82 (2006.01); C12N 9/12 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57426 (2013.01); A61K 31/497 (2013.01); A61K 31/506 (2013.01); C07K 14/82 (2013.01); C12N 9/12 (2013.01); C12Q 1/6883 (2013.01); C07K 2319/00 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/156 (2013.01);
Abstract

A splice variant of bcr-abl mRNA that produces BCR-ABL protein with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is disclosed. Vectors for expressing the truncated gene product are provided as well as recombinant cells that express the truncated gene product from a cDNA construct. Also provided are methods compositions and kits for detecting the BCR-ABL splice variant. Additionally, methods for screening BCR-ABL kinase domain inhibitors which rely on the recombinant cells and methods of predicting likelihood for resistance of a CML patient with a BCR/ABL translocation respond to treatment with one or more BCR-ABL kinase inhibitors are also disclosed.


Find Patent Forward Citations

Loading…